title: New and emerging therapies in psoriasis.
abstract: This article discusses the scientific rationale for the use of cytokine inhibitors, including ustekinumab, an inhibitor of the interleukin (IL)-12 and IL-23 pathways in psoriasis. Also addressed are the efficacy and safety data for this agent, as well as for several emerging therapies that target other cytokine pathways in psoriasis: the IL-17 inhibitors secukinumab, ixekizumab, and brodalumab, the IL-23 blocker tildrakizumab, and the small-molecule kinase inhibitors apremilast (a phosphodiesterase-4 blocker) and tofacitinib (a Janus kinase inhibitor).
authors: Clinical Professor of Dermatology, Saint Louis University, Central Dermatology, St Louis, Missouri.
authors: Craig L
authors: CL
authors: Leonardi
authors: Professor of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
authors: Kenneth B
authors: KB
authors: Gordon
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D006801:Humans; D018664:Interleukin-12 / Q000037:antagonists & inhibitors*; D020381:Interleukin-17 / Q000037:antagonists & inhibitors; D053759:Interleukin-23 / Q000037:antagonists & inhibitors*; D011565:Psoriasis / Q000188:drug therapy*; D000069549:Ustekinumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D020381:Interleukin-17; D053759:Interleukin-23; D018664:Interleukin-12; D000069549:Ustekinumab
keywords: Apremilast; JAK; Janus kinase inhibitors; brodalumab; interleukin-12/23 inhibitors; interleukin-17 inhibitors; ixekizumab; phosphodiesterase-4 inhibitors; psoriasis treatment; secukinumab; tildrakizumab; tofacitinib; tumor necrosis factor inhibitors; ustekinumab